9.58
-1.41(-12.83%)
Currency In USD
Address
75 State Street
Boston, MA 02109
United States of America
Phone
457 070 5210
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
October 29, 2020
| Name | Title | Pay | Year Born |
| Dr. Hans T. Schambye M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Director | 1.03M | 1966 |
| Ms. Lori C. Firmani | Interim Chief Financial Officer | 446,528 | 1973 |
| Mr. Garrett Winslow Esq. | Senior Vice President, General Counsel & Corporate Secretary | 734,792 | 1979 |
| Mr. Ulf J. Nilsson Ph.D. | Co-Founder | 0 | N/A |
| Mr. Matthew Kronmiller | EVice President of Strategy & Chief Business Officer | 0 | 1987 |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder | 0 | N/A |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder | 0 | N/A |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.